Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06341751
Other study ID # 2024-00393-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 11, 2024
Est. completion date April 2025

Study information

Verified date April 2024
Source Karolinska Institutet
Contact Frank Svärdman, psychologist
Phone 0702308870
Email Frank.svardman@ki.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized pilot study to investigate the feasibility and acceptability of a transdiagnostic psychological intervention for primary care patients in Region Stockholm, Sweden, who suffer from persistent and disabling fatigue.


Description:

Previous research indicates that fatigue is a transdiagnostic symptom dimension rather than a disorder-specific pathofysiology. Similar psychosocial mechanisms can contribute to the development and perpetuation of fatigue across medical conditions. Cognitive and behavioral interventions targeting these perpetuating mechanisms have been found effective in reducing fatigue severity and functional impairment in a range of different fatigue-dominated diagnostic groups. Based on these findings, the investigators have developed a transdiagnostic intervention for primary care patients who suffer from persistent fatigue, independent of primary diagnosis. The treatment is a psychological intervention based on cognitive and behavioral principles that is administered over a period of 4-6 months. Treatment material will be delivered via an online treatment platform and therapist support will be given both face-to-face and via written asynchronous text-messages in the online treatment platform. This initial feasibility study is non-randomized, meaning that all included patients will recieve treatment. The project could provide feasibility of a transdiagnostic treatment for primary care patients with severe and persistent fatigue across medical conditions. If the inclusion procedure, the data-collection procedure, and the treatment are feasible, a larger randomized clinical trial (RCT) studying treatment effect is called for. An adequately powered RCT could provide firm scientific support for a novel, scalable, and cost-effective way to deliver an evidence-based treatment for this large and currently under-treated patient group. This would have a desirable impact on patients, families, healthcare units, and society at large, given that fatigue is associated with substantial suffering and work-disability and that treatment guidelines are currently lacking.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 67 Years
Eligibility Inclusion Criteria: 1. age 18-67 2. severe, functionally disabling fatigue as a central symptom for at least 3 months 3. The fatigue is not a direct effect of an active disease process motivating another treatment (e.g., hypo-/hyperthyroidism, anemia, cancer, dementia) or the effect of medication 4. regular access to a computer and to the Internet 5. ability to read and write in Swedish. Exclusion Criteria: 1. substance abuse disorder in the past 6 months 2. Current or past psychosis or bipolar disorder 3. Primary psychiatric disorder of such severity that it merits evidence-based treatment (e.g., obsessive compulsive disorder, moderate to severe depression, post-traumatic stress disorder) 4. elevated risk for suicide 5. anorexia nervosa 6. BMI>40 7. Initiated or changed psychopharmacological medication (e.g., for depression or anxiety disorders) in the past month 8. ongoing chemotherapy 9. intellectual disability (e.g., severe autism) that affects ability to work with the treatment 10. self-harm 11. pregnancy 12. life circumstances that complicate or make treatment impossible (e.g., domestic violence or ongoing legal disputes) 13. ongoing psychological treatment and/or multimodal rehabilitation.

Study Design


Intervention

Behavioral:
Psychological treatment for persistent fatigue
The treatment consists of three main phases: 1) goal-setting; stabilizing sleep-wake patterns and even distribution of activities over the day (pacing). Attention-shifting and cognitive reappraisal 2. Gradual increase in physical activity followed by gradual increase in mental and social activity 3. Individual work to reach treatment goals.

Locations

Country Name City State
Sweden Gustavsberg University Primary Care Clinic Stockholm

Sponsors (4)

Lead Sponsor Collaborator
Karolinska Institutet Forte, Region Stockholm, The Swedish Research Council

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment fidelity Treatment fidelity will be assessed by audio recording all synchronous treatment sessions, of which a random selection will be assessed for fidelity using checklists that correspond to the central treatment components in each phase of the treatment. Continuously throughout the 6-month treatment phase
Other Evaluation of participants' experience of treatment When all treatments have been completed in the study, semi-structured interviews will be conducted with up to 10 included patients and up to three therapists. These will tap deeper, qualitative information about perceptions of working with the treatment and the data-collection procedures. All interviews will be audio recorded and transcribed for thematic content analysis. Post-treatment completion (at 6 months)
Other Acceptability, Appropriateness, and Feasibility from the perspective of the clinic a survey based on the "Triple P Systems Implementation Outcomes: Acceptability, Appropriateness, and Feasibility of intervention measure" will be disseminated to healthcare staff at participating primary health care clinics, to which they respond anonymously. Assessed post-treatment completion (after 6 months)
Primary Treatment adherence and completion Treatment adherence will be assessed by evaluating how many sessions (face-to-face and video-based) the patient received, how many modules of the internet-delivered material the patient accessed, and the amount of time the patient spent in the online treatment platform (data extracted from the platform).
Further, number of drop-outs (i.e., patients who discontinued treatment before treatment completion) will be analyzed
Post-treatment (6 months)
Primary Treatment credibility Assessed using the Credibility/Expectancy Questionnaire (C-Scale). The C-Scale is a 5-item measure, scale range is 0 to 50 points with higher scores indicating higher treatment credibility. Three weeks after treatment start
Primary Patient satisfaction Client Satisfaction Questionnaire (CSQ-8). Total scores range from 8 to 32, with higher scores indicating greater treatment satisfaction. Post-treatment (6 months)
Primary Working alliance Assessed using the Working Alliance Questionnaire (WAI - short version). Scale range is from 6 to 42 with higher scores indicating a better percieved working alliance. Week 3 and 15 of treatment
Primary Negative effects of treatment The Negative Effects of Treatment Questionnaire (NEQ-20). The self-report measure consists of three parts. First, respondents endorse specific items in case they have occurred or not during treatment, yes/no (dummy coded as a variable: 1/0). Second, the respondents rate how negatively the negative effect was on four-point Likert-scale, ranging from "Not at all" to "Extremely", 0-4 ("0" being minimum and "4" being maximum). Third, the respondents attribute the negative effect to "The treatment I received" (1) or "Other circumstances" (0) (dummy coded as a variable: 1/0). Post-treatment (6 months)
Primary Open-ended questions regarding treatment content and presentation Post-treatment, patients will be asked open-ended questions regarding their perception of the different components of the treatment, how much time they spent working with the treatment, and their thoughts about the usability of the digital platform. Post-treatment (6 months)
Secondary Feasibility of study inclusion procedures and data-collection The recruitment procedure will be evaluated by accessing data from ALMA (a fully automated clinical desicion-support in the medical journal). ALMA aggregates anonymous data regarding number of times the algorithm has been activated and the number of times it has resulted in a referral to the study platform where screening for study inclusion is completed. Of those who complete screening, we will assess the proportion of patients who are included or excluded in the study.
Data-collection procedures will be assessed by evaluating data-attrition at the various measurement points.
Data will be collected during the recruitment and inclusion phase of the study.
Secondary Fatigue severity, primary self-rated symptom outcome Fatigue severity (self-rated) using the Checklist Individual Strenghts- Fatigue severity subscale. The domain Fatigue severity contains 8 items scored on a 7-point Likert scale (range 8-56; higher scores=more severe fatigue). A score above 35 points on the CIS-F indicates severe fatigue. Assessed pre- and at post treatment (6 months), and every three weeks during the treatment phase.
Secondary Problems concentrating Subscale in the Checklist Individual Strengths Questionnaire (CIS), 5 items. Scale range: 5 to 35 with higher scores representing more problems concentrating. Assessed pre- and at post treatment (6 months)
Secondary Reduced physical activity Subscale in the Checklist Individual Strengths Questionnaire (CIS), 3 items. Scale range: 3 to 21 with higher scores representing less physical activity. Assessed pre- and at post treatment (6 months)
Secondary Reduced motivation Subscale in the Checklist Individual Strengths Questionnaire (CIS), 4 items. Scale range: 4 to 28 with higher scores representing less motivation. Assessed pre- and at post treatment (6 months)
Secondary Depressive symptoms Patient Health Questionnaire-9 (PHQ-9). Scale range is from 0 to 27, higher scores representing more depressive symptoms Note: the suicide-item will be administered every three weeks during the treatment phase. Assessed pre- and at post treatment (6 months). The individual item assessing suicide risk will be administered every 3 weeks during the traetment phase.
Secondary Somatic symptoms Physical Health Questionnaire-15 (PHQ-15). Scale range is from 0 to 30, higher scores representing more somatic symptoms Assessed pre- and at post treatment (6 months)
Secondary General anxiety The General Anxiety Questionnaire (GAD-7). Scale range is from 0 to 21, higher scores representing more anxiety. Assessed pre- and at post treatment (6 months)
Secondary Insomnia The Insomnia Severity Inventory (ISI) 7 items. Scale range is from 0 to 28, higher scores representing higher insomnia severity.
NOTE: an additional item will be added to assess hypersomnia.
Assessed pre- and at post treatment (6 months), and every three weeks during the treatment phase.
Secondary Perceived Stress The Perceived Stress Scale (PSS-10). Scale range is from 0 to 40, higher scores representing a higher level of perceived stress. Assessed pre- and at post treatment (6 months)
Secondary Burnout The Shirom-Melamed Burnout Questionnaire (SMBQ-18). Scale range is from 0 to 6, higher scores representing a higher level of burnout. Assessed pre- and at post treatment (6 months)
Secondary Self-rated health The Self-rated health questionnaire (SRH-5). A single item with 5 response-categories, 0 (very bad health); 4 (very good health) Assessed pre- and at post treatment (6 months)
Secondary Cognitive and behavioral responses to symptoms Cognitive and Behavioral Responses to Symptoms Questionnaire (CBRQ), 18-items. The scale assesses six domains: Fear avoidance (3 items, scale range 0-12); Damage beliefs (3 items, scale range 0-12); Embarrassment avoidance (3 items, scale range 0-12); Symptom focusing (3 items, scale range 0-12); All-or-nothing behaviour (3 items, scale range 0-12); Resting behaviour (3 items, scale range 0-12). Assessed pre- and at post treatment (6 months), and every three weeks during the treatment phase.
Secondary General self-efficacy The General self-efficacy scale (GSE), 10 items. Scale range is from 10 to 40, higher scores representing a higher level of self-efficacy. Assessed pre- and at post treatment (6 months), and every three weeks during the treatment phase.
Secondary Functional disability World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), 12 items. Scoring from 0 (maximum functional disability) to 100 (no functional disability) Assessed pre- and at post treatment (6 months)
Secondary Work and Social Adjustment the Work and Social Adjustment Scale (WSAS), 5 items. Scale range 0 to 40 with higher scores representing better work and social adjustment. Assessed pre- and at post treatment (6 months)
See also
  Status Clinical Trial Phase
Completed NCT04959214 - The Effect Of Progressıve Relaxatıon Exercıses N/A
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Completed NCT04531891 - Utility and Validity of a High-intensity, Intermittent Exercise Protocol N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT04960865 - Kinesio Taping and Calf Muscle Fatigue N/A
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT06421233 - The Effect of Endorphin Massage Applied to Postpartum Women on Anxiety and Fatigue Levels N/A
Active, not recruiting NCT05344183 - Immediate and Short-term Effects of Low-level Laser N/A
Completed NCT04716049 - Effectiveness of Recovery Protocols in Elite Professional Young Soccer Players N/A
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05241405 - Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer N/A
Active, not recruiting NCT06074627 - Radicle Energy2: A Study of Health and Wellness Products on Fatigue and Other Health Outcomes N/A
Completed NCT03943212 - The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis N/A
Recruiting NCT05567653 - Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers N/A
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT05863897 - e-COGRAT: A Blended eHealth Intervention for Fatigue Following Acquired Brain Injury N/A
Not yet recruiting NCT05002894 - Effect of Pilates Exercises On Fatigue In Post Menopausal Women N/A
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT02911649 - Reducing Sedentary Behaviour With Technology N/A
Completed NCT03216616 - Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases N/A